Literature DB >> 24979543

Tumor necrosis factor inhibitors in psoriasis: an update.

Francisco A Kerdel1, Bruce E Strober2.   

Abstract

Three inhibitors of tumor necrosis factor (TNF) currently are approved for the treatment of psoriasis: etanercept, infliximab, and adalimumab. The other two TNF inhibitors, golimumab and certolizumab pegol, have shown efficacy against plaque psoriasis in clinical trials of psoriatic arthritis (PsA). This article reviews the most recent evidence on the efficacy and safety of the TNF inhibitors in psoriasis, with special attention to preventing and managing immunogenicity. 2014 published by Frontline Medical Communications.

Entities:  

Keywords:  Immunogenicity; TNF; psoriasis treatment; tumor necrosis factor inhibitors

Mesh：

Substances：

Year:  2014        PMID： 24979543     DOI： 10.12788/j.sder.0066

Source DB:  PubMed          Journal:  Semin Cutan Med Surg        ISSN： 1085-5629


  5 in total

1.  Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting.

Authors:  Seemal R Desai; Ilona J Frieden; Joel M Gelfand; Whitney High; Arthur Kavanaugh; Ashfaq A Marghoob; David M Ozog; Ted Rosen; Linda Stein Gold; Bruce Strober; Neil Swanson; George Martin
Journal:  J Clin Aesthet Dermatol       Date:  2015-09

2.  Etanercept-induced myositis: do we have to stop it? A surprising outcome.

Authors:  Hassan Tariq; Bibi Ayesha; Karen Weidenheim; Giovanni Franchin
Journal:  BMJ Case Rep       Date:  2016-01-11

Review 3.  Risks of Biologic Therapy and the Importance of Multidisciplinary Approach for an Accurate Management of Patients with Moderate-Severe Psoriasis and Concomitant Diseases.

Authors:  Ana Ion; Alexandra Maria Dorobanțu; Liliana Gabriela Popa; Mara Mădălina Mihai; Olguța Anca Orzan
Journal:  Biology (Basel)       Date:  2022-05-25

Review 4.  Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events.

Authors:  Smriti Subedi; Yu Gong; Youdong Chen; Yuling Shi
Journal:  Drug Des Devel Ther       Date:  2019-07-23       Impact factor: 4.162

5.  Effectiveness of infliximab biosimilars in the treatment of moderate to severe chronic plaque psoriasis: experience of real-world data from the register of the program "Treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland.

Authors:  Witold Owczarek; Irena Walecka; Agnieszka Nowakowska; Piotr Ciechanowicz; Adam Reich; Aleksandra Lesiak; Ewa Borkowska; Andrzej Śliwczyñski; Joanna Narbutt
Journal:  Postepy Dermatol Alergol       Date:  2021-08-16       Impact factor: 1.664
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.